Cart
sales@molnova.com
Abelacimab
CAS No. 2098724-83-3
Abelacimab( —— )
Catalog No. M36766 CAS No. 2098724-83-3
Abelacimab (MAA868), a fully human IgG1 monoclonal antibody, targets and binds with high affinity to FXI's catalytic structural domain.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 593 | Get Quote |
|
| 5MG | 945 | Get Quote |
|
| 10MG | 1520 | Get Quote |
|
| 25MG | 2475 | Get Quote |
|
| 50MG | 3662 | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameAbelacimab
-
NoteResearch use only, not for human use.
-
Brief DescriptionAbelacimab (MAA868), a fully human IgG1 monoclonal antibody, targets and binds with high affinity to FXI's catalytic structural domain.
-
DescriptionAbelacimab (MAA868) is a fully human IgG1 monoclonal antibody that binds with high affinity to the catalytic structural domain of FXI and locks it in the zymogen conformation, thereby preventing its activation by FXIIa or thrombin. Abelacimab can be used in thromboembolic disease studies.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
RecptorOthers
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number2098724-83-3
-
Formula Weight
-
Molecular Formula——
-
Purity>98% (HPLC)
-
Solubility——
-
SMILES——
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Alexander W Koch, et al. MAA868, a novel FXI antibody with a unique binding mode, shows durable effects on markers of anticoagulation in humans. Blood. 2019 Mar 28;133(13):1507-1516.?
molnova catalog
related products
-
14-hydroxytetradecan...
14-hydroxytetradecanoic acid is a trace compound found in kelp and has potential antimicrobial and antioxidant activity.
-
Oxynitidine
Oxynitidine is an HBV inhibitor (ID50=30.8 μg/mL), which can effectively inhibit the DNA replication activity of HBV. Oxynitidine can be used in the study of viral infections.
-
Soyasaponin Aa
Soyasaponin Aa and soyasaponin Ab dose-dependently markedly inhibit adipocyte differentiation and expression of various adipogenic marker genes, through the downregulation of the adipogenesis-related transcription factors PPARγ and C/EBPα± in 3T3-L1 adipocytes.
